VANCOUVER, BC –August 28, 2020 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) announces that, effective August 27, 2020, Operations Manager Jaclyn Thast has been appointed as Corporate Secretary. Effective August 27, 2020, Robert Thast has resigned from his position as Corporate Secretary of the Company and remains as Chief Executive Officer, President and a Director.
Ms. Thast has been carrying out many of the duties and executing documentation normally undertaken by the Corporate Secretary and has been responsible for all corporate and public company administration requirements since joining the Izotropic team as Operations Manager in 2018. She has and continues to be a key contributor to the company and a highly valued member of the Management Team.
The board wishes to thanks Ms. Thast for her contributions to date and formally welcome her to the new role of Corporate Secretary.
ON BEHALF OF THE BOARD
About Izotropic Corp.
Izotropic Corporation and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast. Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.
The Company has the exclusive worldwide license from the University of California, Davis (UC Davis) to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company’s breast CT imaging platform.
Approximately $20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, ongoing $2.9M U.S. clinical trial at UC Davis Medical Center.
The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.